The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial

Michael E. Nassif, Sheryl L. Windsor, Barry A. Borlaug, Dalane W. Kitzman, Sanjiv J. Shah, Fengming Tang, Yevgeniy Khariton, Ali O. Malik, Taiyeb Khumri, Guillermo Umpierrez, Sumant Lamba, Kavita Sharma, Sadiya S. Khan, Lokesh Chandra, Robert A. Gordon, John J. Ryan, Sunit Preet Chaudhry, Susan M. Joseph, Chen H. Chow, Manreet K. KanwarMichael Pursley, Elias S. Siraj, Gregory D. Lewis, Barry S. Clemson, Michael Fong, Mikhail N. Kosiborod

Research output: Contribution to journalArticlepeer-review

Original languageEnglish (US)
Pages (from-to)1954-1960
Number of pages7
JournalNature Medicine
Volume27
Issue number11
DOIs
StatePublished - Nov 2021

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint

Dive into the research topics of 'The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial'. Together they form a unique fingerprint.

Cite this